Immunotherapy in Cutaneous Oncology: Revolutionizing Treatment Approaches  

作　　者：Abigail Beard Sydney DeVore Kelly Frasier Sandhya Palit Alexandra Loperfito Lacey M. Miller Michelle Sobotka Abigail Beard;Sydney DeVore;Kelly Frasier;Sandhya Palit;Alexandra Loperfito;Lacey M. Miller;Michelle Sobotka(Heritage College of Osteopathic Medicine, Ohio University, Dublin, Ireland;School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA;Vassar Brothers Medical Center, Nuvance Health, Poughkeepsie, NY, USA;ESIC Medical College, Chennai, India;Edward Via College of Osteopathic Medicine, Blacksburg, VA, USA;School of Osteopathic Medicine, A.T. Still University, Mesa, AZ, USA;Midwestern College of Osteopathic Medicine, Glendale, AZ, USA)

机构地区：[1]Heritage College of Osteopathic Medicine, Ohio University, Dublin, Ireland [2]School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA [3]Vassar Brothers Medical Center, Nuvance Health, Poughkeepsie, NY, USA [4]ESIC Medical College, Chennai, India [5]Edward Via College of Osteopathic Medicine, Blacksburg, VA, USA [6]School of Osteopathic Medicine, A.T. Still University, Mesa, AZ, USA [7]Midwestern College of Osteopathic Medicine, Glendale, AZ, USA

出　　处：《Journal of Biosciences and Medicines》2024年第11期80-93,共14页生物科学与医学（英文）

摘　　要：Background: Cutaneous oncology encompasses a broad range of skin malignancies, including melanoma, cutaneous squamous cell carcinoma (SCC), and basal cell carcinoma (BCC), all of which pose significant global health challenges. The World Health Organization (WHO) estimates that melanoma incidence has increased by approximately 50% over the past three decades. While SCC and BCC are generally less aggressive than melanoma, they contribute significantly to the overall burden of skin cancer due to their high prevalence. Traditional treatment modalities for these malignancies, such as surgery, radiation, and chemotherapy, have shown limitations in achieving durable responses and minimizing systemic toxicity. As a result, there is an increasing need for more effective and less toxic treatment options. Immunotherapeutic strategies have emerged as a promising avenue in oncology, with the potential to revolutionize treatment approaches for cutaneous malignancies. Objectives: This literature review aims to undertake an in-depth examination of immunotherapeutic strategies for melanoma, SCC, and BCC. Specifically, the review focuses on the role of immune checkpoint inhibitors, adoptive cell therapies, and emerging immunotherapies, assessing their impact on treatment outcomes, survival rates, and patient quality of life. Methods: A literature search was conducted using databases such as PubMed, Google Scholar, and Scopus. The search terms included “cutaneous oncology”, “immunotherapy”, “immune checkpoint inhibitors”, “adoptive cell therapy”, “melanoma”, “cutaneous squamous cell carcinoma”, and “basal cell carcinoma”. Peer-reviewed articles published in the last 10 years that reported clinical outcomes from immunotherapy-based treatments for cutaneous malignancies were included. The studies were reviewed and analyzed based on their reported clinical outcomes, including survival rates, adverse events, and quality of life metrics. Results: Our review identified significant advancements in immunotherapBackground: Cutaneous oncology encompasses a broad range of skin malignancies, including melanoma, cutaneous squamous cell carcinoma (SCC), and basal cell carcinoma (BCC), all of which pose significant global health challenges. The World Health Organization (WHO) estimates that melanoma incidence has increased by approximately 50% over the past three decades. While SCC and BCC are generally less aggressive than melanoma, they contribute significantly to the overall burden of skin cancer due to their high prevalence. Traditional treatment modalities for these malignancies, such as surgery, radiation, and chemotherapy, have shown limitations in achieving durable responses and minimizing systemic toxicity. As a result, there is an increasing need for more effective and less toxic treatment options. Immunotherapeutic strategies have emerged as a promising avenue in oncology, with the potential to revolutionize treatment approaches for cutaneous malignancies. Objectives: This literature review aims to undertake an in-depth examination of immunotherapeutic strategies for melanoma, SCC, and BCC. Specifically, the review focuses on the role of immune checkpoint inhibitors, adoptive cell therapies, and emerging immunotherapies, assessing their impact on treatment outcomes, survival rates, and patient quality of life. Methods: A literature search was conducted using databases such as PubMed, Google Scholar, and Scopus. The search terms included “cutaneous oncology”, “immunotherapy”, “immune checkpoint inhibitors”, “adoptive cell therapy”, “melanoma”, “cutaneous squamous cell carcinoma”, and “basal cell carcinoma”. Peer-reviewed articles published in the last 10 years that reported clinical outcomes from immunotherapy-based treatments for cutaneous malignancies were included. The studies were reviewed and analyzed based on their reported clinical outcomes, including survival rates, adverse events, and quality of life metrics. Results: Our review identified significant advancements in immunotherap

关 键 词：Cutaneous Oncology Advanced Melanoma IMMUNOTHERAPY TREATMENT Novel Treatment Approaches 

分 类 号：R73[医药卫生—肿瘤]